OR WAIT 15 SECS
Spanish-based healthcare company, Grifols, announced that FDA approved the expansion of the plasma fractionation unit at its Clayton, North Carolina facility.
Grifols announced on Nov. 17, 2014 that FDA approved the installation of a blood plasma unit at its plant in Clayton, North Carolina. According to Reuters, the plant will increase Grifol’s plasma fractionation, extracting proteins from plasma, capacity by six million liters of plasma per year.
Grifols currently has four FDA-approved plasma derivative production plants: Barcelona, Spain; Los Angeles, California; Melville, New York; and Clayton. Grifols analyzes every unit of donated plasma at the laboratories to test for Hepatitis A, B, or C, HIV, and parvovirus B19.
Related Content:Bio/Pharma Business